Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment entities : Athenex, inc. save search
Actinic Keratosis Treatment Market Size Worth $8.12 Billion By 2028: Grand View Research, Inc.
Published: 2021-10-28 (Crawled : 09:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.79%
H: 0.6%
C: 0.6%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.38%
H: 2.05%
C: 1.37%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.66%
H: 0.76%
C: 0.04%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 0.32%
H: 0.47%
C: -0.9%
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 1.19%
H: 2.75%
C: -0.39%
treatment actinic keratosis research
Athenex Announces Phased European Launch of Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis
Published: 2021-09-27 (Crawled : 14:00) - biospace.com/
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 0.93%
H: 4.0%
C: 0.92%
treatment actinic keratosis europe tirbanibulin
Almirall receives European Commission approval of Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis
Published: 2021-07-19 (Crawled : 21:00) - biospace.com/
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: -2.26%
H: 1.8%
C: -0.77%
treatment actinic keratosis europe approval tirbanibulin
Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis
Published: 2021-07-19 (Crawled : 15:00) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: -2.26%
H: 1.8%
C: -0.77%
treatment actinic keratosis europe approval tirbanibulin
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: -6.69%
H: 1.46%
C: -6.05%
treatment fda cancer breast cancer metastatic breast cancer
Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or ScalpEuropean Commission Decision Anticipated by July 2021
Published: 2021-05-21 (Crawled : 16:00) - biospace.com/
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 1.04%
H: 1.85%
C: -1.85%
treatment actinic keratosis europe positive tirbanibulin chmp ema
Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis
Published: 2021-05-21 (Crawled : 14:00) - prnewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 1.04%
H: 1.85%
C: -1.85%
treatment actinic keratosis positive tirbanibulin chmp
Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp
Published: 2021-05-21 (Crawled : 14:00) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 1.04%
H: 1.85%
C: -1.85%
treatment actinic keratosis europe positive tirbanibulin chmp ema
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
Published: 2021-05-20 (Crawled : 13:00) - prnewswire.com
SEEL | $0.3502 3.61% 3.48% 290K
|
Health Technology
|
| O: -3.36%
H: 6.96%
C: 4.43%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 4.24%
H: 5.93%
C: 3.73%
MRKR | $4.25 3.65% 3.52% 15K
|
Consumer Services
|
| O: -0.42%
H: 7.14%
C: 5.88%
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: -0.2%
H: 0.79%
C: -5.12%
treatment cancer growth pancreatic pancreas
Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer
Published: 2021-03-01 (Crawled : 12:03) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: -54.96%
H: 12.84%
C: 0.18%
treatment fda cancer breast cancer response metastatic breast cancer
Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp
Published: 2020-12-15 (Crawled : 12:02) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 3.34%
H: 1.57%
C: -9.06%
fda approval fda approval actinic keratosis treatment tirbanibulin
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.